The company is a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions.
Biostar chief executive officer and chairman Ronghua Wang said in April 2012, during an industry-wide investigation by SFDA, 254 drug manufacturers in 28 provinces were found to use gel capsules that had a chromium content higher than edible gelatin.
"As a result, SFDA suspended sales of gel capsules until the investigation was completed. As previously disclosed, during this investigation, one batch of samples of our Xin Aoxing capsule was found to have chromium content higher than edible gelatin," Wang added.
"The cessation of sales of gel capsule products has severely affected all China-based pharmaceutical companies that use gelatin capsules to manufacture their drugs, including Biostar."
The company took all the necessary measures to restart sales of gel capsule drugs immediately after the anticipated receipt of the approval from the SFDA.